Fruquintinib-Sintilimab Combo Approved for Kidney Cancer in China
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
nmpakidney-cancer
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
China's National Medical Products Administration (NMPA) granted approval on May 21, 2026, for the combination of fruquintinib and sintilimab as a first-line treatment for advanced renal cell carcinoma (RCC). The regulatory milestone validates a novel immuno-oncology approach outside the dominant PD-1 inhibitor plus CTLA-4 inhibitor paradigm. This approval creates a new competitive dynamic in the Chinese oncology market, which is projected to reach $2.4 billion for RCC treatments by 2028.
The approval arrives amid a global shift toward combination therapies for difficult-to-treat cancers. Renal cell carcinoma has a five-year survival rate below 15% for metastatic cases, creating significant unmet medical need. The last major first-line RCC approval in China was Merck's Keytruda plus Lenvima combination in late 2024, which showed a median overall survival of 31.2 months.
Current Chinese regulatory policy strongly favors domestically developed innovative drugs to reduce reliance on expensive imported therapies. The NMPA's Center for Drug Evaluation has prioritized review pathways for novel combinations that demonstrate superior efficacy over standard of care. This strategic focus accelerated the fruquintinib-sintilimab application through the approval process.
The Phase III FRUIT-RCC trial met its primary endpoint of progression-free survival in November 2025. Data showed a 45% reduction in risk of progression or death compared to sunitinib, the previous standard of care. This significant clinical benefit provided the conclusive evidence required for final regulatory endorsement.
The FRUIT-RCC trial enrolled 512 patients with previously untreated metastatic RCC. Patients receiving the combination therapy demonstrated a median progression-free survival of 16.8 months. This compares favorably to the 9.2 months observed in the sunitinib control arm.
Objective response rate, a key secondary endpoint, reached 58.7% for the fruquintinib-sintilimab group. The sunitinib group achieved a 35.4% response rate. Treatment-related adverse events of grade 3 or higher occurred in 68% of combination therapy patients versus 52% in the control group.
The Chinese RCC drug market generated approximately $1.7 billion in sales during 2025. This represents a 12% year-over-year growth from the $1.52 billion recorded in 2024. Analysts project the market will expand to $2.4 billion by 2028, driven by new treatment options and improved diagnosis rates.
| Metric | Fruquintinib-Sintilimab | Sunitinib (Control) |
|---|---|---|
| Median PFS | 16.8 months | 9.2 months |
| Objective Response Rate | 58.7% | 35.4% |
| Grade 3+ Adverse Events | 68% | 52% |
The approval directly benefits Hutchison China MediTech (HCM) and Innovent Biologics, the developers of fruquintinib and sintilimab, respectively. HCM's stock could see a 5-8% revaluation as analysts incorporate peak sales estimates of $350-500 million for the new RCC indication. Innovent gains expanded use for its PD-1 inhibitor, potentially adding $200-300 million to its sintilimab revenue stream.
Global pharmaceutical leaders Merck and Bristol-Myers Squibb face increased competitive pressure in the Chinese RCC market. Keytruda and Opdivo currently command dominant market shares exceeding 60% combined. Pricing pressure is likely as the domestic combination offers a clinically competitive alternative at a potentially lower cost.
A primary risk involves the combination's safety profile, which showed higher rates of severe adverse events. This may limit its use in older patients or those with comorbidities, constraining the total addressable market. Hospital formulary adoption will be the critical near-term indicator of commercial success.
Institutional investors have been accumulating positions in Chinese biotech firms with late-stage pipelines since the fourth quarter of 2025. The approval validates this investment thesis and may trigger further flows into the sector. Short interest in HCM declined 15% in the week preceding the announcement, indicating anticipated positive news.
The next immediate catalyst is the publication of the full FRUIT-RCC trial data in a peer-reviewed journal, expected by Q3 2026. Detailed subgroup analyses will reveal which patient populations derive the greatest benefit from the combination therapy. This data will guide oncologists' treatment decisions and influence reimbursement policies.
Investors should monitor the pricing announcement from China's National Healthcare Security Administration, due during the annual National Reimbursement Drug List negotiations in December 2026. Inclusion on the NRDL is crucial for widespread adoption and will determine the therapy's commercial trajectory. The outcome will signal the government's willingness to fund innovative domestic combinations.
Key technical levels to watch include HCM's stock price holding above the HK$35 support level, which has held since February 2026. A sustained break above HK$42 would confirm bullish momentum and likely attract further institutional buying. For the broader CSI 300 Healthcare Index, the 12,000 level represents a critical resistance point that has capped advances twice in the past year.
Sintilimab is a PD-1 inhibitor that blocks a key pathway cancer cells use to evade the immune system. Fruquintinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor that cuts off the tumor's blood supply. The combination simultaneously attacks the cancer through immunotherapy and anti-angiogenesis, creating a synergistic effect that has proven more effective than either approach alone in renal cell carcinoma.
Merck's Keytruda, often used in combination with Lenvima, currently leads the first-line RCC market in China. The fruquintinib-sintilimab approval introduces a clinically competitive domestic alternative that may capture 15-20% market share within two years. This will likely pressure Keytruda's pricing power and growth trajectory in China, though its established position and strong data will maintain a significant presence. Merck may respond with targeted discounts or additional clinical data to reinforce its value proposition.
Clinical trials are ongoing for the fruquintinib-sintilimab combination in several other solid tumors. A Phase III trial in advanced hepatocellular carcinoma is expected to report data in early 2027. Phase II studies are active in non-small cell lung cancer and endometrial cancer. Positive results in these additional indications could significantly expand the addressable patient population and peak sales potential beyond the renal cell carcinoma opportunity.
The NMPA approval establishes a new, effective first-line treatment for kidney cancer and strengthens China's domestic drug innovation ecosystem.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.